- GYRE Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
10-K/A Filing
Gyre Therapeutics (GYRE) 10-K/A2018 FY Annual report (amended)
Filed: 29 Apr 19, 12:00am
Exhibit 31.4
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Fletcher Payne, certify that:
| 1. | I have reviewed this annual report on Form 10-K/A of Catalyst Biosciences, Inc. (this “report”); and |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report. |
Date: April 26, 2019
/s/ Fletcher Payne
Fletcher Payne
Chief Financial Officer
We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.